ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY

被引：0
|
作者：
Chang, Xiujuan [1 ]
Yu, Shumin [1 ,2 ]
Pang, Jianzhi [1 ]
Zhang, Wei [1 ]
Kong, Huifang [1 ]
Huang, Jiagan [1 ]
Zhang, Guojie [1 ]
Zhang, Huixin [1 ]
Gu, Yueyue [1 ,3 ]
Dong, Zheng [1 ]
Chen, Yan [1 ]
Yang, Bin [1 ]
Liu, Jingping [4 ]
Yang, Yongping [1 ]
Zeng, Zhen [1 ,2 ,3 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[2] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[3] Anhui Med Univ, Sch Clin Med 5, Hefei, Anhui, Peoples R China
[4] Elect Power Hosp Beijing, Beijing, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4402
引用
收藏
页码：S1305 / S1306
页数：2
相关论文
共 50 条
  • [41] Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study
    Li, Xingzhi
    Wang, Xiaobo
    Bai, Tao
    Chen, Jie
    Tang, Zhihong
    Wei, Tao
    Lu, Shaolong
    Li, Lequn
    Wu, Feixiang
    JOURNAL OF HEPATOLOGY, 2023, 78 : S581 - S582
  • [42] Effectiveness of anti-PD-1 for hepatocellular carcinoma
    Liao, Rui
    LANCET ONCOLOGY, 2020, 21 (06): : E293 - E293
  • [43] Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
    Qu, Wei-Feng
    Ding, Zhen-Bin
    Qu, Xu-Dong
    Tang, Zheng
    Zhu, Gui-Qi
    Fu, Xiu-Tao
    Zhang, Zi-Han
    Zhang, Xin
    Huang, Ao
    Tang, Min
    Tian, Meng-Xin
    Jiang, Xi-Fei
    Huang, Run
    Tao, Chen-Yang
    Fang, Yuan
    Gao, Jun
    Wu, Xiao-Ling
    Zhou, Jian
    Fan, Jia
    Liu, Wei-Ren
    Shi, Ying-Hong
    BJS OPEN, 2022, 6 (05):
  • [44] Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
    Meng, Lingzhan
    Li, Hu
    Ji, Yingjie
    Yu, Peng
    Wang, Zizheng
    Cao, Li
    Shi, Bin
    Shao, Yanling
    Yan, Jin
    Gao, Yinjie
    Zhu, Zhenyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [45] Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study (vol 14, 1109771, 2023)
    Li, Shuqun
    Wu, Junyi
    Wu, Jiayi
    Fu, Yangkai
    Zeng, Zhenxin
    Li, Yinan
    Li, Han
    Liao, Weijia
    Yan, Maolin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy
    Sheng, Ruofan
    Zeng, Mengsu
    Jin, Kaipu
    Zhang, Yunfei
    Wu, Dong
    Sun, Huichuan
    ACADEMIC RADIOLOGY, 2022, 29 (06) : 819 - 829
  • [47] Combination of donafenib and anti-PD-1 antibody plus trans-arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC).
    Gu, Shanzhi
    Tan, Yulin
    Zhou, Huan
    Hu, Hongtao
    Zheng, Tongsen
    Zheng, Zhendong
    Zhu, Xu
    Yuan, Mu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16197 - E16197
  • [48] Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy
    Xin, Yujing
    Peng, Gang
    Song, Wei
    Zhou, Xiang
    Huang, Xiaoyu
    Cao, Xiaojing
    FRONTIERS IN GENETICS, 2024, 15
  • [49] Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
    Xin, Yujing
    Zhang, Xinyuan
    Liu, Ning
    Peng, Gang
    Huang, Xiaoyu
    Cao, Xiaojing
    Zhou, Xiang
    Li, Xiao
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 753 - 764
  • [50] Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
    Yujing Xin
    Xinyuan Zhang
    Ning Liu
    Gang Peng
    Xiaoyu Huang
    Xiaojing Cao
    Xiang Zhou
    Xiao Li
    Hepatology International, 2023, 17 : 753 - 764
12345